Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trabectedin versus trabectedin plus tTF-NGR in metastatic or refractory soft tissue sarcoma
2020-005858-21Phase 3Active
- Sponsor
- Universität Münster
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of trabectedin and tTF-NGR in soft tissue sarcoma (STS) and Liposarcoma (2 arms), sponsored by Universität Münster. Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
trabectedintTF-NGR
03
Conditions
soft tissue sarcoma (STS)Liposarcoma
Beyond the preview
Go deeper on 2020-005858-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005858-21.